TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11395039

Group type: EXPERIMENTAL
Intervention: Soluble P-selectin levels in patients with unstable coronary artery disease (n=44)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Soluble P-selectin levels in patients with stable atherosclerotic disease (n=32)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Plasma level of soluble P-selectin as a predictor of unstable coronary syndrome
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Correlation of soluble P-selectin with alpha-tocopherol levels
Number of subjects: 76
Study: 9571379

Group type: EXPERIMENTAL
Intervention: Persons with paraplegia
Number of subjects: 677

Group type: COMPARATOR
Intervention: Non-disabled persons
Number of subjects: 677
Study: 7826564

Group type: EXPERIMENTAL
Intervention: Monatepil monotherapy (30 mg/day initially, titrated to 60 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monatepil in combination with ACE inhibitors (15 mg/day initially, titrated to 60 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monatepil in combination with beta-blockers (15 mg/day initially, titrated to 60 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (during 4-week control period)
Number of subjects: 0
Study: 3417080

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine at 19.00 h
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine at 22.00 h
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29566729

Group type: EXPERIMENTAL
Intervention: Maternal hyperoxygenation (100% oxygen supplied to the mother by a non-rebreathing mask until delivery)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Maternal hyperoxygenation
Number of subjects: 116

Group type: COMPARATOR
Intervention: Normal care (control group)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 116
Study: 27424564

Group type: EXPERIMENTAL
Intervention: Tunnel technique using collagen matrix (CM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Tunnel technique using connective tissue graft (CTG)
Number of subjects: 28
Study: 25122130

Group type: EXPERIMENTAL
Intervention: Health Belief Model (HBM) intervention
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) intervention
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study: 23882458

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel
Number of subjects: 80

Group type: COMPARATOR
Intervention: dry dressing (placebo)
Number of subjects: 80
Study: 22029737

Group type: EXPERIMENTAL
Intervention: Condensed video‐based individual coaching sessions (15 min.) supported by a manual and a DVD.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting control group (not receiving the intervention).
Number of subjects: 40
Study: 19219666

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Bupropion-SR
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 17007850

Group type: EXPERIMENTAL
Intervention: Saline infusion sonohysterography (SIS)
Number of subjects: 1009
Study: 12920686

Group type: EXPERIMENTAL
Intervention: Zenith AAA Endovascular Graft
Number of subjects: 352

Group type: COMPARATOR
Intervention: Conventional surgical repair
Number of subjects: 352
Study: 10963999

Group type: EXPERIMENTAL
Intervention: Female condom intervention with education program on use of female and male condoms and STDs.
Number of subjects: 1929

Group type: COMPARATOR
Intervention: Control communities received information on use of male condoms.
Number of subjects: 1929
Study: 8817802

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2285642

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 100
Study: 7015020

Group type: EXPERIMENTAL
Intervention: Cephalothin (antibiotic)
Number of subjects: 211
Study: 31092196

Group type: EXPERIMENTAL
Intervention: RB stock solution 10 mg/ml (Group 1)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Two-fold dilution 5 mg/ml (Group 2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Three-fold dilution 3.3 mg/ml (Group 3)
Number of subjects: 39
Study: 27735922

Group type: EXPERIMENTAL
Intervention: Simplified consent form
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional consent form
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Review/retest intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lowest education group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher quiz scores
Number of subjects: 0
Study: 25820113

Group type: EXPERIMENTAL
Intervention: Nebulization of ropivacaine 150 mg before surgery
Number of subjects: 140

Group type: COMPARATOR
Intervention: Instillation of ropivacaine 150 mg before surgery
Number of subjects: 140
Study: 24791343

Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream
Number of subjects: 156

Group type: COMPARATOR
Intervention: Metronidazole 1% gel
Number of subjects: 156
Study: 21806591

Group type: EXPERIMENTAL
Intervention: Multimodal analgesic protocol (n=47)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (n=45)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study: 19204205

Group type: EXPERIMENTAL
Intervention: docetaxel, doxorubicin, and cyclophosphamide (TAC)
Number of subjects: 1350

Group type: COMPARATOR
Intervention: fluorouracil, doxorubicin, and cyclophosphamide (FAC)
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: TAC
Number of subjects: 1350
Study: 16707961

Group type: EXPERIMENTAL
Intervention: Intracoronary radiotherapy with Rhenium liquid-filled angioplasty balloon system
Number of subjects: 165

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Intracoronary radiotherapy
Number of subjects: 165
Study: 15343588

Group type: EXPERIMENTAL
Intervention: Exenatide-primed arm (subcutaneous exenatide starting at 0.02 micro g/kg TID, increasing every 3 days for 35 days)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Exenatide-primed arm
Number of subjects: 123

Group type: COMPARATOR
Intervention: Exenatide-naive arm (placebo TID for 35 days)
Number of subjects: 123
Study: 11156782

Group type: EXPERIMENTAL
Intervention: Combined intraarterial/intravenous thrombolysis with 50 mg actilyse (maximal dose, 0.7 mg/kg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Thrombolysis group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 9797806

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined multimodal therapy (surgery and/or radiotherapy with chemotherapy)
Number of subjects: 0
Study: 7639376

Group type: EXPERIMENTAL
Intervention: Epidural butorphanol 30 micrograms/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous butorphanol 30 micrograms/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epidural morphine 60 micrograms/kg
Number of subjects: 60
Study: 3281411

Group type: EXPERIMENTAL
Intervention: 0.75 microgram alphacalcidol
Number of subjects: 65
Study: 28919502

Group type: EXPERIMENTAL
Intervention: Memory foam pad (group A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Bean bag with shoulder braces (group B)
Number of subjects: 43
Study: 27535349

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 8000

Group type: COMPARATOR
Intervention: Enoxaparin/VKA
Number of subjects: 8000
Study: 24656286

Group type: EXPERIMENTAL
Intervention: Echocardiographic assessment at baseline pump speed and at each 1,000-rpm interval from 8,000 rpm to 11,000 rpm
Number of subjects: 52
Study: 23036149

Group type: EXPERIMENTAL
Intervention: Multi-faceted tailored implementation intervention of a clinical decision support system including interactive education, reminders, monitoring, feedback and leadership.
Number of subjects: 464

Group type: COMPARATOR
Intervention: Hard-copy of the pressure ulcer prevention protocol supported by standardized 30 min group lecture.
Number of subjects: 464
Study: 20189976

Group type: EXPERIMENTAL
Intervention: FCSI-9
Number of subjects: 391
Study: 18437173

Group type: EXPERIMENTAL
Intervention: Prostatectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Androgen ablation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel therapies (kinase inhibitors, antisense oligonucleotides, inhibitors of heat-shock proteins)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeting ETS transcription factors or TMPRSS2-ETS gene fusion
Number of subjects: 0
Study: 16088404

Group type: EXPERIMENTAL
Intervention: Bendamustine, vincristine + prednisone (BOP)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Cyclophosphamide, vincristine + prednisone (COP)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: BOP in responders
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: BOP in responders not receiving interferon maintenance therapy
Number of subjects: 164

Group type: COMPARATOR
Intervention: COP
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: BOP and COP
Number of subjects: 164
Study: 12925153

Group type: EXPERIMENTAL
Intervention: Rebamipide (OA-R)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo (OA-P)
Number of subjects: 206
Study: 11783329

Group type: EXPERIMENTAL
Intervention: Xinyikang Oral Liquid (XYK)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Qidong Yixin oral liquid
Number of subjects: 92
Study: 8981292

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 50 mg daily
Number of subjects: 6602

Group type: EXPERIMENTAL
Intervention: Modified-release dipyridamole 400 mg daily
Number of subjects: 6602

Group type: EXPERIMENTAL
Intervention: Combination of ASA and dipyridamole
Number of subjects: 6602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6602
Study: 8266157

Group type: EXPERIMENTAL
Intervention: Lignocaine spray
Number of subjects: 55

Group type: COMPARATOR
Intervention: Lignocaine gel
Number of subjects: 55
Study: 3541948

Group type: EXPERIMENTAL
Intervention: BCG immunisation therapy
Number of subjects: 40
Study: 31421110

Group type: EXPERIMENTAL
Intervention: Orvepitant 30 mg once daily for 4 weeks
Number of subjects: 13
Study: 28886575

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy with normative feedback
Number of subjects: 252
Study: 26358533

Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention (single home visit and 3-4 follow-up phone calls by a nurse over 90 days)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 67
Study: 24290415

Group type: EXPERIMENTAL
Intervention: Test formulation of miglitol (100 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reference formulation of miglitol (100 mg)
Number of subjects: 40
Study: 23739513

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (monotherapy, daily dosage 0.1 ml/kg, in the morning hours, on each other day, i.m., 30 injections in total) during 2 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no pharmacotherapy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 60
Study: 20978446

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus matuzumab (800 mg weekly)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus matuzumab (1600 mg every 3 weeks)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Pemetrexed alone
Number of subjects: 148
Study: 17900252

Group type: EXPERIMENTAL
Intervention: ARVD/C patients
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 42
Study: 16884981

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-ketamine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Propofol-ketamine
Number of subjects: 44
Study: 12844130

Group type: EXPERIMENTAL
Intervention: 1 to 300 pmol/min vasopressin administered by the intrabrachial route
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 pmol/min vasopressin administered by the intrabrachial route
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prolonged continuous infusion of vasopressin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vasopressin with nitric oxide clamp (4 micromol/min L‐N(G)‐monomethylarginine and 0.3 to 0.8 nmol/min sodium nitroprusside)
Number of subjects: 12
Study: 11082411

Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia
Number of subjects: 1732

Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: Nonfatal perioperative outcomes
Number of subjects: 1732
Study: 8803508

Group type: EXPERIMENTAL
Intervention: Partially active recovery (20 min of pedalling at 40% VO2max followed by 40 min of seated rest)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Passive recovery (20 min seated on cycle ergometer followed by 40 min more of seated rest)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Maximal exercise intensity
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: VO2max
Number of subjects: 14

Group type: COMPARATOR
Intervention: Partially active recovery vs passive recovery
Number of subjects: 14
Study: 1307878

Group type: EXPERIMENTAL
Intervention: Artificial intelligence-based systems with complex clinical algorithms tailored to specific patient conditions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Invasive and noninvasive monitoring systems.
Number of subjects: 0
Study: 6401416

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (CS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31489645

Group type: EXPERIMENTAL
Intervention: Algorithm allocating ICD-10-AM codes into 'probable' or 'possible' causes of GIB
Number of subjects: 716

Group type: COMPARATOR
Intervention: Source medical records validation
Number of subjects: 716
Study: 29502984

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg once daily at bedtime
Number of subjects: 595
Study: 26179569

Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program lifestyle intervention (n = 30) consisting of 12 bi‐weekly core sessions and six monthly post‐core sessions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control intervention (n = 30) consisting of quarterly mailing of diabetes prevention information
Number of subjects: 60
Study: 24559487

Group type: EXPERIMENTAL
Intervention: Intermittent aerobic exercise training on a bicycle ergometer, 18 sessions, three times a week
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intermittent aerobic exercise training
Number of subjects: 44
Study: 22869325

Group type: EXPERIMENTAL
Intervention: Easy goal-setting condition
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Difficult goal-setting condition
Number of subjects: 98

Group type: COMPARATOR
Intervention: Do-your-best goal-setting condition (Control)
Number of subjects: 98
Study: 20119647

Group type: EXPERIMENTAL
Intervention: PTX3 levels measured daily for 7 days and then at days 9, 11, 13, 18, 23, and 28.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Day 1 PTX3 levels in septic shock patients.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Day 1 PTX3 levels correlation with clinical parameters.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Day 1 PTX3 levels correlation with coagulation markers.
Number of subjects: 90
Study: 18559700

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS (gastrointestinal therapeutic system)
Number of subjects: 10069
Study: 16053952

Group type: COMPARATOR
Intervention: TNK alone
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: TNK-facilitated angioplasty
Number of subjects: 170
Study: 11994055

Group type: EXPERIMENTAL
Intervention: Treatment A (3.2 mg kg‐1 on day 0 and 1.6 mg kg‐1 on days 1‐4)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Treatment C (3.2 mg kg‐1 on day 0 and 0.8 mg kg‐1 on days 1‐4)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard treatment R (artemether: 3.2 mg kg‐1 on day 0 and 0.8 mg kg‐1 on days 1‐4)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Treatment B (1.6 mg kg‐1 on day 0 and 0.8 mg kg‐1 on days 1‐4)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Treatment C
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard treatment R
Number of subjects: 22
Study: 10424739

Group type: EXPERIMENTAL
Intervention: Oral topotecan with high-fat breakfast
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral topotecan without food
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous topotecan
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral topotecan (fasted)
Number of subjects: 18
Study: 7844666

Group type: EXPERIMENTAL
Intervention: PRP-OMP vaccine after first dose
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: PRP-T vaccine after two doses
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: HbOC vaccine after three doses
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: PRP-OMP followed by HbOC or PRP-T
Number of subjects: 300
Study: 2090783

Group type: EXPERIMENTAL
Intervention: Letter grading system
Number of subjects: 19

Group type: COMPARATOR
Intervention: Pass-fail grading system
Number of subjects: 19
Study: 30132370

Group type: EXPERIMENTAL
Intervention: Sequentially monitored clinical trials that did not stop early for benefit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditional approach to estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bias-adjusted estimate
Number of subjects: 0
Study: 29018021

Group type: EXPERIMENTAL
Intervention: <6 hours sleep per night
Number of subjects: 13026

Group type: EXPERIMENTAL
Intervention: Positive screening for obstructive sleep apnea
Number of subjects: 13026

Group type: EXPERIMENTAL
Intervention: Overnight shift work (≥3 night shifts/week for ≥1 year)
Number of subjects: 13026

Group type: EXPERIMENTAL
Intervention: Presence of all 3 sleep-related risk factors
Number of subjects: 13026
Study: 25926370

Group type: EXPERIMENTAL
Intervention: Threshold IMT (TG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Incentive spirometry (ISG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study: 23168455

Group type: EXPERIMENTAL
Intervention: Face-to-face interview
Number of subjects: 44

Group type: COMPARATOR
Intervention: Postal questionnaire
Number of subjects: 44
Study: 21610487

Group type: EXPERIMENTAL
Intervention: VCT invitations for male sexual partners (MSPs)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: PIS invitations for MSPs
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: VCT arm for MSPs
Number of subjects: 1000

Group type: COMPARATOR
Intervention: PIS arm for MSPs
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: VCT arm for MSPs regarding unprotected sex
Number of subjects: 1000

Group type: COMPARATOR
Intervention: PIS arm for MSPs regarding unprotected sex
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: VCT arm for women regarding unprotected sex
Number of subjects: 1000

Group type: COMPARATOR
Intervention: PIS arm for women regarding unprotected sex
Number of subjects: 1000
Study: 18007263

Group type: EXPERIMENTAL
Intervention: Enteral supplement (500 mL of Intestamin, Fresenius Kabi) containing conditionally essential nutrients
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Immunonutrition formula (experimental group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard formula (control group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Enteral supplement
Number of subjects: 55
Study: 16420512

Group type: EXPERIMENTAL
Intervention: 48-week peginterferon-alpha-2b (80-100 mcg/week) plus ribavirin (1000-1200 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 24-week peginterferon-alpha-2b (80-100 mcg/week) plus ribavirin (1000-1200 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 48-week peginterferon-alpha-2b plus ribavirin in patients with unfavorable predictors
Number of subjects: 60

Group type: COMPARATOR
Intervention: 24-week peginterferon-alpha-2b plus ribavirin in patients with unfavorable predictors
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 48-week peginterferon-alpha-2b plus ribavirin
Number of subjects: 60

Group type: COMPARATOR
Intervention: 24-week peginterferon-alpha-2b plus ribavirin
Number of subjects: 60
Study: 12830603

Group type: EXPERIMENTAL
Intervention: Foley catheter plus titrated oral misoprostol solution
Number of subjects: 526

Group type: COMPARATOR
Intervention: Titrated oral misoprostol solution alone
Number of subjects: 526

Group type: COMPARATOR
Intervention: Vaginal dinoprostone
Number of subjects: 526
Study: 11138880

Group type: EXPERIMENTAL
Intervention: Bicillin CR with procaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bicillin LA
Number of subjects: 50
Study: 9192924

Group type: EXPERIMENTAL
Intervention: Educational programme (Experimental group)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Open Airways programme (Experimental group)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Shortened educational programme (4 weeks)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Standard care without education (Comparison group)
Number of subjects: 312
Study: 1486157

Group type: EXPERIMENTAL
Intervention: Delayed-release indomethacin (Eudragit L formulation)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard indomethacin
Number of subjects: 45
Study: 4033403

Group type: EXPERIMENTAL
Intervention: Exercise (3 d/wk, 8-wk aerobics program at 70-85% maximum heart rate)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-exercise (NE)
Number of subjects: 72
Study: 29781921

Group type: EXPERIMENTAL
Intervention: TRAIN group (16-week high-intensity interval training)
Number of subjects: 55

Group type: COMPARATOR
Intervention: CONT group (non-exercising)
Number of subjects: 55
Study: 27731828

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium 50 mg test (F4) tablet formulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference product (Caflam)
Number of subjects: 12
Study: 24815497

Group type: EXPERIMENTAL
Intervention: Indomethacin (nonselective COX inhibitor)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Celebrex (selective COX-2 inhibitor)
Number of subjects: 12